Treating such diseases of adults as:

• Cryptococcal meningitis;
• coccidioidomycosis;
• invasive candidiasis;
• mucosal candidiasis including oropharyngeal candidiasis, esophageal candidiasis, candiduria, chronic candidiasis of the skin and mucous membranes;
• chronic atrophic candidiasis (candidiasis, caused by the use of dentures) in the ineffectiveness of the local dental hygiene products;
• Vaginal candidiasis, acute or recurrent when local therapy is not appropriate;
• candida balanitis when local therapy is not appropriate;
• dermatomycosis, including athlete's foot, tinea corporis, tinea groin, pityriasis versicolor and candida infections of the skin, when systemic therapy is not appropriate;
• dermatophyte onychomycosis, when the use of other drugs is not relevant.

Prevention of diseases in adults as:

• a relapse of cryptococcal meningitis in patients with high risk of its developing;
• recurrent oropharyngeal candidiasis or esophagus in patients with HIV with a high risk of its developing;
• reducing of the frequency of relapses of vaginal candidiasis (4 or more times a year);
• prevention of Candida infections in patients with prolonged neutropenia (such as patients with malignant blood diseases who are receiving chemotherapy or in patients with hematopoietic stem cell transplantation).